In an effort to clamp down on corruption, China sentenced its former top drug regulator to death on Tuesday.
In an effort to clamp down on corruption, China sentenced its former top drug regulator to death on Tuesday.
Zheng Xiaoyu, who served as director of China’s State Food and Drug Administration (SFDA) from 1997 to 2006, was convicted on several counts of bribery. According to Chinese newswire Xinhua, Xiaoyu accepted gifts totaling nearly $850,000 from eight unnamed pharmaceutical companies to approve their drugs.
"(Zheng's acts) greatly undermined the integrity of an official post and the efficiency of China's drug monitoring and supervision, endangered public life and health, and had a very negative social impact," Xinhua quoted the Beijing Municipal No. 1 Intermediate People’s Court as saying.
Much like the old Chinese proverb, this might be a case of killing the chicken to scare the monkey. The weighty sentence, says one anonymous insider, was delivered as a fear tactic-not because the drugs might have killed people. The Chinese SFDA is strictly in the business of approving drugs, while quality control is left to the General Administration of Quality Supervision, Inspection, and Quarantine.
“This isn’t the first time an official has received the death penalty in China,” says J. Benjamin Bai, a principal at international law firm Jones Day. “This might be shocking to the Western world because in the United States, politicians don’t get their heads cut off because of corruption.” Bai admits, however, that executions aren’t the norm. Typically, high-ranking officials are forced to vacate their position or pay restitution.
The Chinese court said that manufacturers of the six drugs approved by Zheng had provided fake documentation when seeking approval. The Associated Press reported "one antibiotic approved by Zheng's agency killed at least 10 patients last year before it was taken off the market."
“Situations like these, where fake drugs are approved or poison makes it into pet products, are a huge deal in China,” Bai says. “This type of corruption is not acceptable in China and they are taking it very seriously.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.